Logo Coronavir.org

Coronavir.org

Site de veille et d'information sur le nouveau coronavirus SARS-COV-2 et la maladie associée COVID-19

Actualités et recherches en cours

Introduction Breakthrough infections in reference to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported worldwide in both partially or completely vaccinated individuals irrespective of the type of vaccine. India, also emerged as the vaccine powerhouse producer, initiating the worlds one of the largest vaccination drives since January 16, 2021, with two vaccines named, BBV-152(COVAXINTM) and AZD1222 (COVISHIELDTM). Br...

The SARS-CoV-2 vaccine BBV152/Covaxin is well-tolerated and was shown to be 77.8% efficacious against symptomatic and 93.4% efficacious against severe symptomatic COVID-19 disease in adults. Previous studies have shown that sera from Covaxin vaccinated individuals have neutralizing activity against B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), B.1.1.28 (Zeta), and B.1.617.1 (Kappa) SARS-CoV-2 variants. The B.1.1.529 variant (Omicron) recen...

This is a protocol for a systematic review to assess fomite transmission in SARS-CoV-2. Our research questions are as follows: 1. Are fomite samples infectious? 2 If so, what proportion are infectious, and what is the distance and duration of infectiousness in the air? 3. What is the relationship between fomites, infectiousness and PCR cycle threshold (Ct)? 4. Is there evidence of a chain of transmission that establishes an actual instance of fo...

Vaccine hesitancy, which potentially leads to refusal or delayed acceptance of COVID-19 vaccines, is considered a key driver for the increasing death toll from the pandemic in the E.U.. European Commission and several member states governments are either planning or have already directly or indirectly announced mandatory vaccination for individuals aged over 60, the group repeatedly proved to be the most vulnerable. In this paper, an assessment ...

NDV-HXP-S is a recombinant Newcastle disease virus based-vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be produced in embryonated chicken eggs using the same process as that employed for the production of influenza virus vaccines. Here we performed a secondary analysis of the antibody responses after vaccination with inactivated N...

This study compares the frequency of hospital-to-hospital transportation events and associated life-threatening deterioration during transport among patients with acute lower respiratory tract illness during vs before the COVID-19 pandemic....

We measured SARS-CoV-2 seroprevalence in cohorts of children, parents and school personnel in 55 randomly selected schools in the canton of Zurich, Switzerland. In June-September 2020, seroprevalence was low (4.4% to 5.8%) in all cohorts. In March-April 2021, seroprevalence in children and parents (18.1% and 20.9%) was slightly higher than in school personnel (16.9%). Children's seroprevalence was slightly higher in classes with infected main te...

Background: Understanding and measuring the individual level of immune protection and its persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory for the management of the vaccination booster campaign. Our prospective study was designed to assess the immunogenicity of the BNT162b2 mRNA vaccine in triggering the humoral and the cellular immune response in healthcare workers up to 6 months after two doses vaccinat...

INTRODUCTION We provide national estimates of the real-world Vaccine effectiveness (VE) based on nationally available surveillance data. The study aimed to estimate the effectiveness of the inactivated Covid-19 vaccine BBIBP-CorV (Vero Cells) Sinopharm vaccine currently deployed in Morocco to reduce the risk of hospitalization from a severe infection of SARS- CoV-2 virus within 9 months after vaccination. METHODS We conducted a test-negative, ca...

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S-specific total and neutralizing antibody (Ab) responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19 vaccin...

Important : Le contenu diffusé sur Coronavir.org ne doit jamais remplacer les conseils d'un médecin ou des autorités de santé locales.